摘要
目的:探讨微小RNA-17-5p(miRNA-17-5p)在慢加急性肝衰竭合并乙型肝炎(HBV-ACLF)患者中的表达水平及其与自噬相关蛋白Beclin1、微管相关蛋白1轻链3-Ⅱ(LC3-Ⅱ)表达的相关性。方法:选取2019年2月至2020年5月HBV-ACLF住院患者82例为HBV-ACLF组,选取同期住院治疗的慢性乙型肝炎(CHB)患者79例作为CHB组,选取同期健康体检者86例作为对照组。采用实时荧光定量PCR(qRT-PCR)法检测血清miRNA-17-5p水平;酶联免疫吸附(ELISA)法检测血清Beclin1、LC3-Ⅱ、总胆红素、白蛋白水平;PCR结合荧光探针的体外扩增技术测定血清HBV DNA载量;Pearson法分析HBV-ACLF患者血清miRNA-17-5p与Beclin1、LC3-Ⅱ、总胆红素、白蛋白、HBV DNA载量的相关性;受试者工作特征曲线(ROC)分析血清miRNA-17-5p、Beclin1、LC3-Ⅱ水平对HBV-ACLF的诊断价值;多因素Logistic回归分析影响HBV-ACLF发生的因素。结果:HBV-ACLF组患者血清Beclin1、LC3-Ⅱ、总胆红素水平高于CHB组和对照组,miRNA-17-5p、白蛋白低于CHB组和对照组(P<0.05);CHB组患者血清Beclin1、LC3-Ⅱ、总胆红素水平高于对照组,miRNA-17-5p、白蛋白低于对照组(P<0.05);HBV-ACLF组患者血清HBV DNA载量高于CHB组(P<0.05)。HBV-ACLF组患者血清miRNA-17-5p水平与Beclin1、LC3-Ⅱ呈负相关(r=-0.580、-0.511;均P<0.05);Beclin1、LC3-Ⅱ与总胆红素、HBV DNA载量均呈正相关,与白蛋白呈负相关(P<0.05);miRNA-17-5p与总胆红素、HBV DNA载量均呈负相关,与白蛋白呈正相关(P<0.05)。血清miRNA-17-5p、Beclin1、LC3-Ⅱ水平诊断HBV-ACLF的曲线下面积(AUC)分别为0.862、0.784、0.886,特异性分别为88.4%、80.2%、81.4%,敏感度分别为74.4%、63.4%、81.7%;三者联合诊断的AUC为0.915,特异性为88.4%,敏感度为82.9%。Beclin1、HBV DNA载量是影响HBV-ACLF发生的独立危险因素(P<0.05),miRNA-17-5p是影响HBV-ACLF发生的保护因素(P<0.05)。结论:HBV ACLF患者血清miRNA-17-5p表达水平降低,与Beclin1、LC3-Ⅱ呈明显负相关,且三者均对HBV-ACLF有一定的诊断价值。
Objective:To investigate the expression level of microRNA-17-5p(miRNA-17-5p)in patients with acute-on-chronic liver failure complicated with hepatitis B(HBV-ACLF)and its correlation with autophagy related protein Beclin1 and microtubule associated protein 1 light chain 3-Ⅱ(LC3-Ⅱ).Methods:A total of 82 patients with HBV-ACLF from February 2019 to May 2020 were selected as HBV-ACLF group,and 79 patients with chronic hepatitis B(CHB)in the same period were selected as CHB group;at the same time,86 healthy people were selected as the control group.The level of serum miRNA-17-5p was detected by real-time fluorescence quantitative PCR(qRT-PCR);the levels of serum Beclin1,LC3-Ⅱ,total bilirubin and albumin were detected by enzyme-linked immunosorbent assay(ELISA);the serum HBV DNA load was measured by PCR combined with fluorescence probe amplification in vitro;Pearson method was used to analyze the corre-lation between serum miRNA-17-5p and Beclin1,LC3-Ⅱ,total bilirubin,albumin and HBV DNA load in HBV-ACLF patients;receiver operating characteristic curve(ROC)was used to analyze the diagnostic value of serum miRNA-17-5p,Beclin1 and LC3-Ⅱlevels in HBV-ACLF;multivariate Logistic regression analysis was used to analyze the factors influencing the occurrence of HBV-ACLF.Results:The levels of serum Beclin1,LC3-Ⅱand total bilirubin in HBV-ACLF group were higher than those in CHB group and control group,while the miRNA-17-5p and albumin were lower than those in CHB group and control group(P<0.05);the levels of serum Beclin1,LC3-Ⅱand total bilirubin in CHB group were higher than those in control group,while miRNA-17-5p and albumin were lower than those in control group(P<0.05);the serum HBV DNA load in HBV-ACLF group was higher than that in CHB group(P<0.05).The serum miRNA-17-5p level of HBV-ACLF patients was negatively correlated with Beclin1,LC3-Ⅱ(r=-0.580,-0.511;P<0.05),total bilirubin and HBV DNA load;Beclin1 and LC3Ⅱwere positively correlated with total bilirubin and HBV DNA load,but negatively correlated with albumin(P<0.05);miRNA-17-5p was negatively correlated with total bilirubin and HBV DNA load,but positively correlated with albumin(P<0.05).The area under the curve(AUC)of serum miRNA-17-5p,Beclin1 and LC3-Ⅱlevels in the diagnosis of HBV-ACLF was 0.862,0.784 and 0.886,the specificity was 88.4%,80.2%,81.4%,and the sensitivity was 74.4%,63.4%and 81.7%,respectively;the AUC of the combined diagnosis was 0.915,the specificity was 88.4%,and the sensitivity was 82.9%.Beclin1 and HBV DNA load were independent risk factors of HBV-ACLF(P<0.05),and miRNA-17-5p was a protective factor(P<0.05).Conclusion:The expression level of serum miRNA-17-5p in patients with HBV-ACLF is decreased,and it is negatively correlated with Beclin1 and LC3-Ⅱ.All of them have certain diagnostic value for HBV-ACLF.
作者
范金虎
王莉娟
李艳
FAN Jin-hu;WANG Li-juan;LI Yan(Department of Hepatology,the Fourth People's Hospital of Huai'an(Huai'an Jiangsu,223002)China)
出处
《中西医结合肝病杂志》
CAS
2022年第2期114-118,共5页
Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases
基金
淮安市自然科学研究计划(No.HAB201944)。